DASATINIB
dasatinib 50 mg tablet, 60
DASATINIB (12865D)
12865D
Manner of administration:Oral
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial treatment - third-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 5 | DPMQ: $421.56 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||